CyFlow CD86 FITC (RUO)
| 品番 | CU421823 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD86 FITC,BU63 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 推奨使用量 | - | ||
| 容量 | 2 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 FITC (CD051682) |
||
| 反応性|交差吸着 | Human | レーザー | Blue |
| 抗原 | CD86, B70, B7-2 | 最大蛍光波長 | 518 nm |
| クローン | BU63 | 最大励起波長 | 490 to 495 nm |
| ホスト | Mouse | 標識/Format | FITC |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu CD86 FITC,BU63
特異性
The mouse monoclonal antibody BU63 recognizes CD86 antigen, a 70 kDa type I transmembrane glycoprotein of immunoglobulin supergene family, expressed on professional antigen-presenting cells, such as dendritic cells, macrophages or activated B lymphocytes.
抗原情報
CD86 (B7-2) and CD80 (B7-1) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CD152 (CTLA-4). Both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, both molecules can also substitute for each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, Banchereau J: B70/B7‑2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J·Exp·Med. 1994·Nov·1; 180(5):1841‑7. <·PMID:·7525840·>
• Chan A, Baird M, Mercer AA, Fleming SB: Maturation and function of human dendritic cells are inhibited by orf virus‑encoded interleukin‑10. J·Gen·Virol. 2006·Nov; 87(11):3177‑81. <·PMID:·17030850·>
• Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·>
• Engel P, Gribben JG, Freeman GJ, Zhou LJ, Nozawa Y, Abe M, Nadler LM, Wakasa H, Tedder TF: The B7‑2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood. 1994·Sep·1; 84(5):1402‑7. <·PMID:·7520767·>
• Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M: Suppression of colon inflammation by CD80 blockade: evaluation of two murine models of inflammatory bowel disease. Inflamm·Bowel·Dis. 2008·Jan·9; <·PMID:·21061388·>
• Giguere JF, Bounou S, Paquette JS, Madrenas J, Tremblay MJ: Insertion of host‑derived costimulatory molecules CD80 (B7.{01} and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J·Virol. 2004·Jun; 78(12):6222‑32. <·PMID:·15163715·>
• Hovden AO, Karlsen M, Jonsson R, Aarstad HJ, Appel S: Maturation of monocyte derived dendritic cells with OK432 boosts IL‑12p70 secretion and conveys strong T‑cell responses. BMC·Immunol. 2011·Jan·5; 12:2. <·PMID:·21208424·>
• Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007·Mar·15; 109(6):2545‑52. <·PMID:·17132718·>
• Mauri D, Wyss-Coray T, Gallati H, Pichler WJ: Antigen‑presenting T cells induce the development of cytotoxic CD4+ T cells (I): Involvement of the CD80‑CD28 adhesion molecules. J·Immunol. 1995·Jul·1; 155(1):118‑27. <·PMID:·7541409·>
• Thomas IJ, Petrich de Marquesini LG, Ravanan R, Smith RM, Guerder S, Flavell RA, Wraith DC, Wen L, Wong FS: CD86 has sustained costimulatory effects on CD8 T cells. J·Immunol. 2007·Nov·1; 179(9):5936‑46. <·PMID:·17947667·>
• Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG: CD80 (B7‑1 and CD86 (B7‑2 are functionally equivalent in the initiation and maintenance of CD4+ T‑cell proliferation after activation with suboptimal doses of PHA. DNA·Cell·Biol. 2002·Mar; 21(3):137‑49. <·PMID:·12015893·>
• Yadav D, Judkowski V, Flodstrom-Tullberg M, Sterling L, Redmond WL, Sherman L, Sarvetnick N: B7‑2 (CD86 controls the priming of autoreactive CD4 T cell response against pancreatic islets. J·Immunol. 2004·Sep·15; 173(6):3631‑9. <·PMID:·15356107·>
• Zhan H, Towler HM, Calder VL: The immunomodulatory role of human conjunctival epithelial cells. Invest·Ophthalmol·Vis·Sci. 2003·Sep; 44(9):3906‑10. <·PMID:·12939308·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>